How innovative business models can make a positive social impact by improving access to quality medicines for women regardless of where they live, their insurance status, or whether they can pay will be the topic for the Feb. 12 WDI Global Impact Speaker Series. Sally Stephens, chief business officer of Medicines 360, will discuss the organization's global focus and how it is driven to meet an unmet need for women around the world, including in the U.S. That is, affordable, long-acting contraceptives. Medicines360 has the only nonprofit pharmaceutical company with a marketed product in the U.S. Its first product is a hormonal intrauterine device, or IUD, which had been out of reach for many women because of the high cost of the sole brand on the market. Medicines360 offers its FDA-approved Liletta at a discounted price to public sector clinics across the U.S. to increase access to this important family-planning product. Additionally, Medicines360 has been working with international health organizations to offer the product, branded as Avibela in low- and middle-income countries, to also increase access to these markets. Avibela was launched in Madagascar in 2018. Sales of Liletta in the U.S. help fund research and development efforts by the company to bring contraceptives to countries such as Madagascar. Stephens will discuss the history of Medicines360, its successes and its plans to expand access to its affordable medicines and products for women.